Eurand N.V. (EURX) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 8 PAGES: 35

More Info
									                 Eurand N.V. (EURX) - Financial and Strategic Analysis Review

       Reference Code: GDPH56330FSA                                                                                      Publication Date: JUL 2010

       Olympic Plaza, Fred.                   Phone                                                 Revenue
                                                               +31 20 6732744                                         121 (million EUR)
       Roeskestraat 123
       Amsterdam                              Fax                                                   Net Profit        -5.90 (million EUR)
       1076 EE                                Website          www.eurand.com                       Employees         620
       Netherlands                            Exchange         EURX [NASDAQ]                        Industry          Pharmaceuticals & Healthcare

      Company Overview
       Eurand N.V. (Eurand) is a pharmaceutical company engaged in the development, manufacturing and commercialization of
       enhanced pharmaceutical and biopharmaceutical products. It utilises its proprietary drug formulation technologies such as
       Bioavailability Enhancement, Controlling Drug Release, Dosage Form and Drug Targeting to develop a diverse product portfolio
       in a range of therapeutic areas. The company’s lead product EUR-1008 is pancreatic enzyme replacement product (PEP) used
       for the treatment of Exocrine Pancreatic Insufficiency (EPI), which is approved by FDA on June 2008. The company is
       headquartered in Amsterdam, Netherlands.

      Key Executives                                                                SWOT Analysis
                    Name                                  Title                     Eurand N.V., SWOT Analysis
      Gearoid M. Faherty                   Chairman                                 Strengths                  Weaknesses

      Rolf A. Classon                      Director
                                                                                    Successful Integration              Limited Distribution Network
      William J. Jenkins, MD               Director
      Nicholas J. Lowcock                  Director                                 Patents and Proprietary             Dependence on Small Group
                                                                                    Technology                          of Customers
      Angelo C. Malahias                   Director
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData
                                                                                    Opportunities                       Threats
      Share Data
       Eurand N.V.                                                                  Product Pipeline                    Competition from Generic
       Share Price (EUR) as on 20-Jul-2010                                8.60                                          Products

                                                                         -0.13      Target Market: Exocrine
       EPS (EUR)
                                                                                    Pancreatic Insufficiency            Dependence on Sole Supplier
       Market Cap (million EUR)                                            320

       Enterprise Value (million EUR)                                      304

       Shares Outstanding (million)                                            48   Source: Annual Report, Company Website, Primary and Secondary Research
       Source: Annual Report, Company Website, Primary and Secondary Research       GlobalData
       G
								
To top